Secondary bacterial infections in patients with coronavirus disease 2019-associated pneumonia
Open Access
- 1 February 2022
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 68 (2) , 142-146
Abstract
The vast majority of patients who hospitalized with coronavirus disease 2019 are given empirical antibiotic therapy. However, information on the frequency, microorganism species, and resistance rates of secondary bacterial infections in coronavirus disease 2019 patients are insufficient. We aimed to show the frequency of secondary infections and resistance conditions in patients with coronavirus disease 2019 hospitalized in the intensive care unit. The results of tracheal aspirate culture, blood culture, and urine culture obtained from coronavirus disease 2019 patients - at least 2 days after their admission to the intensive care unit - were examined microbiologically. A total of 514 patients hospitalized in intensive care unit were included in our study. Tracheal aspirate, blood, or urine cultures were collected from 369 patients (71.8%). Bacterial reproduction was detected in at least one sample in 171 (33.3%) of all patients. The rate of respiratory tract infection and/or bloodstream infection was found to be 21%. Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa in tracheal aspirate culture; Coagulase-negative staphylococci, K. pneumoniae, and A. baumannii in blood culture; and Escherichia coli, K. pneumoniae, and Enterococcus faecalis in urine culture were the most common microorganisms. A. baumannii was resistant to most antibiotics except colistin and P. aeruginosa strains were resistant to most antibiotics except amikacin, colistin, cefepime, and imipenem. In K. pneumoniae, the highest meropenem sensitivity (73%) was observed; there was a strong resistance to most of the remaining antibiotics. We think that our study can be useful in choosing empirical antibiotic therapy in the coronavirus disease 2019 pandemic and reducing the mortality that may occur with secondary infection.Keywords
This publication has 15 references indexed in Scilit:
- Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort studyClinical Microbiology and Infection, 2021
- Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysisClinical Microbiology and Infection, 2020
- Bacterial co‐infections with SARS‐CoV‐2IUBMB Life, 2020
- SARS‐CoV‐2, bacterial co‐infections, and AMR: the deadly trio in COVID‐19?EMBO Molecular Medicine, 2020
- Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect?Clinical Infectious Diseases, 2020
- Co-infections: potentially lethal and unexplored in COVID-19The Lancet Microbe, 2020
- Bacterial and fungal infections in COVID-19 patients: A matter of concernInfection Control & Hospital Epidemiology, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Secondary Bacterial Infections Associated with Influenza PandemicsFrontiers in Microbiology, 2017
- Bacterial Coinfection in InfluenzaJAMA, 2013